Nirmatrelvir-Ritonavir and Viral Load Rebound in Covid-19

SARS-CoV-2 Viral Rebound Cases of SARS-CoV-2 viral load rebound have been reported after a 5-day course of nirmatrelvir-ritonavir. Investigators evaluating viral load rebound among high-risk patients found similar results with nirmatrelvir-ritonavir and placebo.

Automated summary

Viral load rebound of SARS-CoV-2 has been reported after a 5-day treatment course of nirmatrelvir-ritonavir. Investigators have found similar results in terms of viral load rebound between nirmatrelvir-ritonavir and placebo among high-risk patients.